Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Brazil, Germany, and internationally. The company offers products in various therapeutic areas, including cardiovascular, central nervous system, gastro-intestinal, and women healthcare; and dermatology, diabetology, pain management, gynecology, oncology, and anti-infective, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.

Revenue projections:

Revenue projections for TORNTPHARM
Revenue projections for TORNTPHARM

Investors may be wary of TORNTPHARM as its revenues are expected to fall below the prior year's levels. A revenue decrease often leads to concerns about profitability, as it is likely to affect the company's bottom line, prompting investors to take a more cautious approach.

Financial Ratios:

currentRatio 0.00000
forwardPE 39.36155
debtToEquity 42.81000
earningsGrowth 0.19800
revenueGrowth 0.11200
grossMargins 0.75869
operatingMargins 0.26149
trailingEps 59.22000
forwardEps 0.00000

TORNTPHARM's positive earnings and revenue growth suggest that the company is expected to expand its business. This reflects a healthy financial outlook, as TORNTPHARM's increasing profits and sales signal further growth in the near future.
TORNTPHARM's positive gross and operating margins reflect strong financial performance. These metrics indicate that the company is efficiently managing its operations and generating healthy profits, contributing to a solid financial position.

Price projections:

Price projections for TORNTPHARM
Price projections for TORNTPHARM

TORNTPHARM's price projections have been revised upward over time, suggesting that analysts are becoming more confident in the company's future. This trend points to increased optimism about TORNTPHARM's ability to grow.

Insider Transactions:

Insider Transactions for TORNTPHARM
Insider Transactions for TORNTPHARM


TORNTPHARM saw 1 buy transactions, with market price of 3224.449951171875.There were no buy transactions throughout the period under consideration.TORNTPHARM's current price levels are experiencing more selling than buying, which may suggest further declines. If the trend persists, it could lead to a continued downward trajectory as investors lose confidence in the stock's future performance.

Recommendation changes over time:

Recommendations trend for TORNTPHARM
Recommendations trend for TORNTPHARM


TORNTPHARM has received a favorable buy bias from analysts recently, positioning it as a solid investment opportunity. This sentiment may attract more investors, who view TORNTPHARM as a stable option to park their money and potentially benefit from the company's continued growth and profitability.